We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
Consensus vs. actual, and revenue trend
Consensus PT $13.58 · 6 analysts
Stored first · Google News · Yahoo Finance (English)
Abacus Global Management Launches Abx Longevity Growth and Income Fund - marketscreener.com
Abacus Global Management Launches Abx Longevity Growth and Income Fund marketscreener.com
NYSE Content Update: Women's Health Equity Funding Up 41% in 2025 Report
Abacus Global Management Launches First Registered Interval Fund for Longevity Assets - Quiver Quantitative
Abacus Global Management Launches First Registered Interval Fund for Longevity Assets Quiver Quantitative
Abacus Global Management Launches ABX Longevity Growth and Income Fund (ABXGX)
Abacus Global Management to host Investor Day l... - Pluang
Abacus Global Management to host Investor Day l... Pluang
Abacus Global Management Announces Virtual Livestream Details for Investor Day at the New York Stock Exchange on Thursday, July 16th, 2026
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $0.24 | — | — | $66.23M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.05 | — | — | $44.14M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.09 | — | — | $78.71M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.01 | — | — | $50.56M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 08. | Piper Sandler | — | Maintain | Neutral → Neutral | — | Piper Sandler: Neutral |
| 2026. 04. 08. | Piper Sandler | — | Maintain | Neutral → Neutral | — | Piper Sandler: Neutral |
| 2026. 03. 13. | Piper Sandler | — | Downgrade | Overweight → Neutral | — | Piper Sandler: Overweight → Neutral |
| 2025. 12. 23. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2025. 10. 09. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
As of FY2023Q1 · Source: SEC/DART + price data
No holdings data to show.